Biofrontera (BFRI) Non Operating Investment Income (2022 - 2025)
Biofrontera's (BFRI) quarterly Non Operating Investment Income came in at -$1000.0 in Q4 2025, up 50.0% year-on-year from -$666.67 in Q4 2024, and down 200.0% quarter-over-quarter from $1000.0 in Q3 2025.
Biofrontera (BFRI) Non Operating Investment Income (2022 - 2025) Analysis & Trends
Biofrontera's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$1000.0 for Q4 2025.
- On a quarterly basis, Non Operating Investment Income rose 50.0% year-over-year to -$1000.0 in Q4 2025; TTM through Sep 2025 was -$1000.0, a 99.87% increase from a year earlier, with the FY2025 full-year figure at $2000.0, up 114.29% from the prior year.
- Non Operating Investment Income fell to -$1000.0 in Q4 2025 per BFRI's latest filing, from $1000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q4 2022 and bottomed at -$2.9 million in Q1 2023.
- The 4-year median for Non Operating Investment Income is -$2000.0 (2024), against an average of -$473916.7.
- Across the five-year window, Non Operating Investment Income plunged 144.99% in 2023 and surged 150.0% in 2025, its largest moves.
- Year by year, Non Operating Investment Income stood at $1.7 million in 2022, then plunged by 144.99% to -$786000.0 in 2023, then soared by 99.75% to -$2000.0 in 2024, then surged by 50.0% to -$1000.0 in 2025.
- Per Business Quant, the three latest BFRI Non Operating Investment Income figures stand at -$1000.0 (Q4 2025), $1000.0 (Q3 2025), and $2000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Biofrontera | 10.73 Mn | 4.32 Mn | 14.09 Mn | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | -786,000.00 |
| Dec 31, 2023 | -786,000.00 |
| Sep 30, 2023 | -2.21 Mn |
| Sep 30, 2023 | -2.21 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.48 Mn |